Coronary Artery Disease News and Research

Latest Coronary Artery Disease News and Research

Exercise and lifestyle changes are key to improve heart health

Exercise is a wonderful way of boosting heart health, but it's proving to be a tough sell in Ontario South Asian communities, Dr. Milan Gupta told the Canadian Cardiovascular Congress 2009, co-hosted by the Heart and Stroke Foundation and the Canadian Cardiovascular Society.

26 Oct 2009

Obese patients less likely to achieve cholesterol and blood pressure control

Obese patients taking medications to lower their blood pressure and cholesterol levels are less likely to reach recommended targets for these cardiovascular disease risk factors than their normal weight counterparts, according to new research presented at the 2009 Canadian Cardiovascular Congress hosted by the Canadian Cardiovascular Society and the Heart and Stroke Foundation of Canada.

26 Oct 2009

CHMP grants positive opinion to extend the use of Angiox to patients undergoing PCI

The Medicines Company announced today that the Committee for Medicinal Products for Human Use (CHMP) has granted a positive opinion applicable to all Member States of the European Union/European Economic Area that will extend the use of Angiox (bivalirudin) to include patients with heart attacks (so-called ST segment elevation myocardial infarction (STEMI)) undergoing emergency heart procedures called primary percutaneous coronary intervention (PCI).

24 Oct 2009

Learn to recognise stroke symptoms and take action: World Stroke Organization

The theme of this year's World Stroke Day on 29th October is "What can I do?". As the World Stroke Organization says, everyone can do something: learn to recognise symptoms and take action, learn to recognise the risk factors and take action.

24 Oct 2009

King Pharmaceuticals receives FDA complete response letter for CorVue NDA

King Pharmaceuticals, Inc. announced today that the U.S. Food and Drug Administration (FDA) issued a complete response letter regarding the New Drug Application (NDA) for CorVue™ (binodenoson) for injection.

21 Oct 2009

Three deaths in Detroit Marathon highlight the importance of greater public awareness about SDC

The tragic deaths of three runners in Sunday's Detroit Marathon underscore how frequently and indiscriminately sudden cardiac arrest strikes Americans, the Sudden Cardiac Arrest Association said today.

20 Oct 2009

Boehringer Ingelheim Pharmaceuticals receives NDA approval from FDA for its Micardis Tablets 80 mg

Boehringer Ingelheim Pharmaceuticals, Inc. announced today that the U.S. Food and Drug Administration (FDA) approved the supplemental New Drug Application (sNDA) for its angiotensin II receptor blocker (ARB) Micardis® (telmisartan) Tablets 80 mg for reduction of the risk of myocardial infarction, stroke, or death from cardiovascular causes in patients 55 years of age or older at high risk of developing major cardiovascular events who are unable to take angiotensin-converting enzyme (ACE) inhibitors.(1) MICARDIS is the most studied ARB in this high-risk patient population and has been commercially available to treat hypertension (high blood pressure) since its approval in 1998.

19 Oct 2009

Coronary angiography does not affect kidney functioning in CKD patients, reveals study

A screening test that measures whether a patient's heart is healthy enough for a kidney transplant is not as dangerous as once thought, according to a study appearing in an upcoming issue of the Clinical Journal of the American Society Nephrology (CJASN).

19 Oct 2009

Research to investigate and improve patient adherence to prescription drug therapies

CVS Caremark is sponsoring research to investigate patient adherence to prescription drug therapies and identify ways to increase adherence. Working with researchers from Harvard and Brigham and Women's Hospital, the company expects knowledge gained from the research will help health professionals better understand patient behavior and lead to developing programs that health care providers and pharmacies can use to improve medication adherence and ultimately help improve patient care and medical outcomes by avoiding costly hospital treatment.

15 Oct 2009

Abbott announces financial results for the third quarter ended Sept. 30, 2009

Abbott (NYSE: ABT) today announced financial results for the third quarter ended Sept. 30, 2009.

14 Oct 2009

Medtronic commences study of the Zotarolimus-Eluting Peripheral Stent System for treating erectile dysfunction

Medtronic, Inc., announced today the initiation of a feasibility study of an interventional treatment for erectile dysfunction (ED) that uses a specially-designed drug-eluting stent system.

14 Oct 2009

Underwriters exercise their over-allotment option in purchasing additional Stereotaxis' shares

Stereotaxis, Inc. announced today that the underwriters for the recently announced public offering of Stereotaxis common stock have exercised in full their over-allotment option to purchase an additional 975,000 shares of the Company's common stock. The 7,475,000 shares of Stereotaxis common stock in the offering, including the 975,000 shares subject to the over-allotment option, are being sold at a price to the public of $4.00 per share.

12 Oct 2009

Stereotaxis to offer 6,500,000 shares to the public at $4.00 per share

Stereotaxis, Inc. announced today that it had priced the public offering of 6,500,000 shares of its common at a price to the public of $4.00 per share. Stereotaxis has granted the underwriters of the offering an option to purchase up to an additional 975,000 shares of common stock to cover over-allotments, if any. All of the shares in the offering are being offered by Stereotaxis. Stereotaxis expects the offering to close on October 15, 2009.

9 Oct 2009

Stereotaxis receives commitment letter from Silicon Valley Bank

Stereotaxis, Inc. today announced that it has received a commitment letter from Silicon Valley Bank, a member company of SVB Financial Group (Nasdaq: SIVB), to increase and extend its credit facility.

7 Oct 2009

Award-winning GWTG hospitals have lower mortality rates for heart attack and heart failure patients: Study

Hospitals receiving performance awards from the American Heart Association's Get With The Guidelines (GWTG) quality improvement initiative have lower mortality rates for heart attack and heart failure patients than all other hospitals, according to a new study.

7 Oct 2009

Gene therapy to improve ailing heart's contractions of muscle cells

Scientists from the Universities of Michigan and Minnesota show in a research report published online in the FASEB Journal (http://www.fasebj.org) that gene therapy may be used to improve an ailing heart's ability to contract properly. In addition to showing gene therapy's potential for reversing the course of heart failure, it also offers a tantalizing glimpse of a day when "closed heart surgery" via gene therapy is as commonly prescribed as today's cocktail of drugs.

6 Oct 2009

ALL initiative three-year clinical observational study results published

A program that bundled two generic, low-cost drugs - a cholesterol-lowering statin and a blood pressure-lowering drug - and gave daily doses to 68,560 people with diabetes or heart disease for two years is estimated to have prevented 1,271 heart attacks and strokes in the first year following the study period, according to a Kaiser Permanente study published online in the American Journal of Managed Care.

3 Oct 2009

Cost-effective screening test for coronary artery disease

A simple, non-invasive test appears to be an effective screening tool for identifying patients with silent heart disease who are at risk for a heart attack or sudden death.

1 Oct 2009

Cordis Corporation, Boston Scientific enter agreement to resolve Palmaz infringement suit

Cordis Corporation (“Cordis”) announced today that it has reached an agreement with Boston Scientific (“Boston”) resolving its Palmaz infringement suit relating to Boston’s NIR stent, settling several other cardiology-related cases relating to patents in the Ding, Kastenhofer, Palmaz, and Fontirroche patent families, and exchanging paid-up licenses for certain intellectual properties.

30 Sep 2009

$10 million grant to Weill Cornell Institute from NIMH to study geriatric depression

The Weill Cornell Institute of Geriatric Psychiatry at NewYork-Presbyterian Hospital/Westchester Division announced today it has received the largest grant in its 20-year history. One of a handful awarded nationally, the new $10 million, five-year "Center Grant" from the National Institute of Mental Health (NIMH) will enable NewYork-Presbyterian/Weill Cornell investigators to advance their pioneering work in understanding the biological, medical, cognitive and psychosocial problems of depressed seniors.

25 Sep 2009

Coronary Artery Disease News and Research

Latest Coronary Artery Disease News and Research

Exercise and lifestyle changes are key to improve heart health

Obese patients less likely to achieve cholesterol and blood pressure control

CHMP grants positive opinion to extend the use of Angiox to patients undergoing PCI

Learn to recognise stroke symptoms and take action: World Stroke Organization

King Pharmaceuticals receives FDA complete response letter for CorVue NDA

Three deaths in Detroit Marathon highlight the importance of greater public awareness about SDC

Boehringer Ingelheim Pharmaceuticals receives NDA approval from FDA for its Micardis Tablets 80 mg

Coronary angiography does not affect kidney functioning in CKD patients, reveals study

Research to investigate and improve patient adherence to prescription drug therapies

Abbott announces financial results for the third quarter ended Sept. 30, 2009

Medtronic commences study of the Zotarolimus-Eluting Peripheral Stent System for treating erectile dysfunction

Underwriters exercise their over-allotment option in purchasing additional Stereotaxis' shares

Stereotaxis to offer 6,500,000 shares to the public at $4.00 per share

Stereotaxis receives commitment letter from Silicon Valley Bank

Award-winning GWTG hospitals have lower mortality rates for heart attack and heart failure patients: Study

Gene therapy to improve ailing heart's contractions of muscle cells

ALL initiative three-year clinical observational study results published

Cost-effective screening test for coronary artery disease

Cordis Corporation, Boston Scientific enter agreement to resolve Palmaz infringement suit

$10 million grant to Weill Cornell Institute from NIMH to study geriatric depression

Sensing a Healthier Future

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Coronary Artery Disease News and Research

Latest Coronary Artery Disease News and Research

Sensing a Healthier Future

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Newsletters you may be interested in